Andrew Kraft to Prostate-Specific Antigen
This is a "connection" page, showing publications Andrew Kraft has written about Prostate-Specific Antigen.
Connection Strength
0.113
-
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
Score: 0.087
-
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
Score: 0.025